Does fast dissociation from the dopamine D2 receptor explain the action of atypical antipsychotics?: A new hypothesis

American Journal of Psychiatry

Volumn 158, Issue 3, 2001, Pages 360-369

  Kapur, S ^a   Seeman, P ^a  

^a CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; ALPHA (2,3 DIMETHOXYPHENYL) 1 [2 (4 FLUOROPHENYL)ETHYL] 4 PIPERIDINEMETHANOL; CLOZAPINE; DOPAMINE; DOPAMINE 2 RECEPTOR; FANANSERIN; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; PROLACTIN; QUETIAPINE; RISPERIDONE; SERTINDOLE;

COMPETITIVE INHIBITION; DISSOCIATION; DOPAMINERGIC TRANSMISSION; DRUG EFFECT; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG RESEARCH; HUMAN; MODEL; MODULATION; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RECEPTOR AFFINITY; RECEPTOR BINDING; RECEPTOR OCCUPANCY; REVIEW; TRANQUILIZING ACTIVITY;

ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; BRAIN; CLOZAPINE; HALOPERIDOL; HUMANS; PIRENZEPINE; PSYCHOTIC DISORDERS; RECEPTORS, DOPAMINE D2; RECEPTORS, DOPAMINE D4; RECEPTORS, SEROTONIN; RISPERIDONE; SCHIZOPHRENIA; TERMINOLOGY; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0035094264     PISSN: 0002953X     EISSN: None     Source Type: Journal    
DOI: 10.1176/appi.ajp.158.3.360     Document Type: Review

References (83)

1. A historical perspective of clozapine
2. New antipsychotics: The present status
3. What makes an antipsychotic "atypical"? Conserving the definition
4. New name for atypical antipsychotics?
5. The history of clozapine
6. Mechanisms of action of atypical antipsychotic drugs
7. Mechanisms of action of atypical antipsychotic drugs: A critical analysis
8. Understanding the mechanism of action of atypical antipsychotic drugs: A review of compounds in use and development
9. The new atypical antipsychotics: A lack of extrapyramidal side-effects and new routes in schizophrenia research
10. Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo: A meta-analysis of randomized controlled trials
11. Controlled, dose-response study of sertindole and haloperidol in the treatment of schizophrenia
12. 2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine: Relation to extrapyramidal side effects
13. 2-dopamine receptor occupancy in relation to antipsychotic drug effects: A double-blind PET study of schizophrenic patients
14. 2 occupancy, clinical response, and side effects: A double-blind PET study of first-episode schizophrenia
15. 2 occupancy and prolactin levels in first episode psychosis
16. Prolactin plasma levels and D-2-dopamine receptor occupancy measured with IBZM-SPECT
17. D-2 dopamine receptor up-regulation, treatment response, neurological soft signs, and extrapyramidal side effects in schizophrenia: Follow-up study with 1-123-iodobenzamide single photon emission computed tomography in the drug-naive state and after neuroleptic treatment
18. 2-dopamine receptor occupancy differs between patients with and without extrapyramidal side effects
19. A new framework for investigating antipsychotic action in humans: Lessons from PET imaging
20. 2 receptor occupancy
21. 2 receptor occupancy levels
22. 2-dopamine receptor occupancy during treatment with typical and atypical neuroleptics
23. In vivo 1231 IBZM SPECT imaging of striatal dopamine-2 receptor occupancy in schizophrenic patients treated with olanzapine in comparison to clozapine and haloperidol
24. Time course of central nervous dopamine-D-2 and 5-HT2 receptor blockade and plasma drug concentrations after discontinuation of quetiapine (Seroquel) in patients with schizophrenia
25. 2 occupancy in low EPS-incidence drugs: PET evidence
26. 2 receptor occupancy of olanzapine in schizophrenia: A PET investigation
27. 2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia
28. 2 dopamine receptor occupancy in the living human brain: A PET study with risperidone
29. 2 dopamine receptor occupancy induced by olanzapine in healthy subjects
30. 2 receptors: Implications for the treatment of schizophrenia
31. 2A receptors: A PET study of chlorpromazine, clozapine, and amisulpride in schizophrenic patients
32. 2 occupancy, clinical response, and side effects: A double-blind PET study of first-episode schizophrenia
33. 2A antagonist fananserin in the treatment of schizophrenia
34. 2 antagonism and EPS benefits: Is there a causal connection?
35. Serotonin-dopamine interaction and its relevance to schizophrenia
36. The ratios of serotonin-2 and dopamine-2 affinities differentiate atypical and typical antipsychotic drugs
37. Characterization of typical and atypical antipsychotic drugs based on in vivo occupancy of serotonin 2 and dopamine 2 receptors
38. 4 receptor antagonist
39. 1 receptor antagonist
40. 2 pKi values
41. Amisulpride, an atypical antipsychotic, in the treatment of acute episodes of schizophrenia: A dose-ranging study vs haloperidol
42. Amisulpride compared with standard neuroleptics in acute exacerbations of schizophrenia: Three efficacy studies
43. Overcoming the neuroleptic-induced deficit syndrome: Clinical observations with remoxipride
44. Improvement of some schizophrenic deficit symptoms with low doses of amisulpride
45. Amisulpride versus placebo in the medium-term treatment of the negative symptoms of schizophrenia
46. Dopamine receptor pharmacology
47. 4 receptors
48. Amisulpride: From animal pharmacology to therapeutic action
49. 2 receptors: Implications for atypical antipsychotic action
50. 2 receptor occupancy by endogenous dopamine in humans
51. 2-dopamine receptors in the monkey brain
52. 2 receptors: An explanation for low receptor occupancy and early clinical relapse upon withdrawal of clozapine or quetiapine
53. Effects of clozapine on cerebral catecholaminergic neurone systems
54. Regional and temporal differences in real-time dopamine efflux in the nucleus accumbens during free-choice novelty
55. Real-time measurement of electrically evoked extracellular dopamine in the striatum of freely moving rats
56. Evidence for striatal dopamine release during a video game
57. Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: Evidence from a novel positron emission tomography method
58. Effects of fluperlapine on dopaminergic systems in rat brain
59. Seroquel: Biochemical profile of a potential atypical antipsychotic
60. Differential effects of haloperidol, clozapine, and fluperlapine on tuberoinfundibular dopamine neurons and prolactin secretion in the rat
61. Olanzapine and clozapine elevate prolactin after every daily dose
62. Effects of intermittent and continuous haloperidol administration on the dopaminergic system in the rat brain
63. Intermittent and continuous haloperidol regimens produce different types of oral dyskinesias in rats
64. Sensitization versus tolerance to the dopamine turnover-elevating effects of haloperidol: The effect of regular/intermittent dosing
65. Tolerance and reverse tolerance to haloperidol catalepsy induced by the difference of administration interval in mice
66. 2 agonist (U-91356A) in MPTP-exposed monkeys
67. Cocaine disposition in the brain after continuous or intermittent treatment and locomotor stimulation in mice
68. Differential effects of intermittent or continuous exposure to cocaine on the hypothalamic-pituitary-adrenal axis and c-fos expression
69. Risperidone in the treatment of patients with chronic schizophrenia: A multi-national, multi-centre, doubleblind, parallel-group study versus haloperidol
70. Positive and negative symptom response to clozapine in schizophrenic patients with and without the deficit syndrome
71. Deficit and non-deficit forms of schizophrenia: The concept
72. The reliability of distinguishing primary versus secondary negative symptoms
73. On schizophrenia and new generation drugs
74. Clozapine for the treatment-resistant schizophrenic: A double-blind comparison with chlorpromazine
75. Clozapine: A comparison with other novel antipsychotics
76. Treatmentresistant schizophrenic patients respond to clozapine after olanzapine non-response
77. Sensitization with clozapine: Beyond the dopamine hypothesis
78. Neurotransmitter interactions in schizophrenia-therapeutic implications
79. Clozapine fails to prevent the development of haloperidol-induced behavioral hypersensitivity in a cotreatment paradigm